Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Chapman

Showing results (951-960 of 1,011) with videos related to

Pageof 102
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 20, 2015
Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT InhibitionRichard D Carvajal, Donald P Lawrence, Jeffrey S Weber, et al.
Kidney International|August 13, 2003
Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohortArlene B Chapman, Lisa M Guay-Woodford, Jared J Grantham, et al.
Journal of the American Heart Association|March 11, 2018
Genome Wide Association Study Identifies the <i>HMGCS2</i> Locus to be Associated With Chlorthalidone Induced Glucose Increase in Hypertensive PatientsSonal Singh, Caitrin W McDonough, Yan Gong, et al.
Journal of the American Society of Nephrology : JASN|January 30, 2016
Predicted Mutation Strength of Nontruncating PKD1 Mutations Aids Genotype-Phenotype Correlations in Autosomal Dominant Polycystic Kidney DiseaseChristina M Heyer, Jamie L Sundsbak, Kaleab Z Abebe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 25, 2020
A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced MelanomaMichael A Postow, Susan J Knox, Debra A Goldman, et al.
Kidney International|December 26, 2019
Detection and characterization of mosaicism in autosomal dominant polycystic kidney diseaseKatharina Hopp, Emilie Cornec-Le Gall, Sarah R Senum, et al.
Science Translational Medicine|August 26, 2021
LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockadeRonglai Shen, Michael A Postow, Matthew Adamow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2019
Treatment Outcomes of Immune-Related Cutaneous Adverse EventsGregory S Phillips, Jennifer Wu, Matthew D Hellmann, et al.
Molecular Cancer Therapeutics|June 12, 2015
Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Non-V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream TeamPatricia M LoRusso, Scott A Boerner, Mary Jo Pilat, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2015
Multiple Gastrointestinal Polyps in Patients Treated with BRAF InhibitorsRavi K Amaravadi, Kathryn E Hamilton, Xiaohong Ma, et al.
Pageof 102

Showing results (951-960 of 1,011) with videos related to

Sort By:
Pageof 102
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 20, 2015
Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT InhibitionRichard D Carvajal, Donald P Lawrence, Jeffrey S Weber, et al.
Kidney International|August 13, 2003
Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohortArlene B Chapman, Lisa M Guay-Woodford, Jared J Grantham, et al.
Journal of the American Heart Association|March 11, 2018
Genome Wide Association Study Identifies the <i>HMGCS2</i> Locus to be Associated With Chlorthalidone Induced Glucose Increase in Hypertensive PatientsSonal Singh, Caitrin W McDonough, Yan Gong, et al.
Journal of the American Society of Nephrology : JASN|January 30, 2016
Predicted Mutation Strength of Nontruncating PKD1 Mutations Aids Genotype-Phenotype Correlations in Autosomal Dominant Polycystic Kidney DiseaseChristina M Heyer, Jamie L Sundsbak, Kaleab Z Abebe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 25, 2020
A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced MelanomaMichael A Postow, Susan J Knox, Debra A Goldman, et al.
Kidney International|December 26, 2019
Detection and characterization of mosaicism in autosomal dominant polycystic kidney diseaseKatharina Hopp, Emilie Cornec-Le Gall, Sarah R Senum, et al.
Science Translational Medicine|August 26, 2021
LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockadeRonglai Shen, Michael A Postow, Matthew Adamow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2019
Treatment Outcomes of Immune-Related Cutaneous Adverse EventsGregory S Phillips, Jennifer Wu, Matthew D Hellmann, et al.
Molecular Cancer Therapeutics|June 12, 2015
Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Non-V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream TeamPatricia M LoRusso, Scott A Boerner, Mary Jo Pilat, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2015
Multiple Gastrointestinal Polyps in Patients Treated with BRAF InhibitorsRavi K Amaravadi, Kathryn E Hamilton, Xiaohong Ma, et al.
Pageof 102